SIZE XSSIZE SMSIZE MDSIZE LG

HOPA Annual Conference 2019

Preconference Sessions

Preconference sessions are extra-fee events and are not included in the price of registration.
blue K= Knowledge-based activity
red A= Application-based activity


Register Now

 Wednesday, April 3
7–11 am

Residency Program Director and Preceptor Development (001)

blue K 0.4 CEUs

Andrea Iannucci, PharmD BCOP; Andrea Landgraf Oholendt, PharmD BCOP; Jane Pruemer, PharmD BCOP FASHP; Nelly Adel, PharmD BCOP BCPS;

Precepting students and residents is a standard component of oncology pharmacy practice. Equipping preceptors with tools for effective feedback, layered learning, precepting in a nontraditional or ambulatory setting, leadership, and professionalism will be beneficial to current and prospective preceptors.

In addition, with the recent changes in the standards for oncology residencies, it is important to understand the current requirements and to discuss details and implementation challenges. This session will review accreditation standards for the design and conduct of a residency program—including requirements related to program purpose, competency areas, goals and objectives, program structure, learning experiences, orientation, use of preceptor roles, evaluation, resident development plans, and continuous residency program improvement. This preconference will include a combination of didactic learning and facilitated small-group discussion.

Learning Objectives

  1. Identify the PGY-2 Oncology Pharmacy Residency disease state, supportive care, and associated therapy requirements.
  2. Propose guidelines to facilitate efficient and meaningful topic discussions.
  3. Generate novel ideas to promote residents’ learning and development.
  4. Identify criteria that will meet American Society of Health-System Pharmacists (ASHP) residency standards for recognition in the area of pharmacy practice for qualified preceptors.
  5. Provide examples of activities that demonstrate evidence of an established, active practice and ongoing professionalism that will meet the criteria for qualified preceptors outlined by the ASHP standards.
  6. Determine whether a pharmacist meets the criteria to serve as a qualified preceptor, when provided with the pharmacist’s academic professional record.
  7. Develop procedures to enhance the PGY-2 Oncology residency program director’s ability to maximally utilize the strengths of the oncology preceptors to enhance the residency program at his or her institution.
  8. Demonstrate the ability to effectively provide high-quality feedback to program preceptors and preceptors in training.
  9. Identify the characteristics of a high-quality preceptor training program.
  10. Employ positive communication skills with patients and healthcare practitioners.
  11. Demonstrate leadership attributes while recommending a modification to any plan, whether it is clinically, operationally, or departmentally related.
  12. Display interest in self-reflection in order to build the various aptitudes of a professional experienced practitioner.

Agenda

  • Quality and Qualified: Ensuring That Quality Oncology Pharmacy Practitioners meet ASHP Standards for Qualified Preceptors
  • Identifying and Managing Required Topics in PGY-2 Oncology Standards
  • Roles and Expectations of a Residency Program Director
  • Fine-Tuning Some Exceptional Skills That an Oncology Resident Should Exhibit

Fee: $125

Preconference-Only Fee: $100


Wednesday, April 3
7–11 am

Palliative Care Toolbox for Oncology Pharmacists (002)

blue K 0.4 CEUs

Developed and presented by the Society of Pain and Palliative Care Pharmacists (SPPCP) Accredited by the Hematology/Oncology Pharmacy Association (HOPA)

Speakers: Benjamin Kematick, PharmD; Victor Phantumvanit, PharmD BCOP BCPS; Bridget Scullion, PharmD BCOP; Iman Suliman, PharmD

Pharmacists in the oncology setting are poised to provide pharmaceutical care to improve patients’ quality of life through symptom management and through detection and prevention of medication-related adverse effects that contribute to an oncology patient’s symptom burden. Palliative care teams rely on pharmacists’ expertise to optimize medication therapy, and oncology pharmacists have an opportunity to develop palliative care skills with the oncology and palliative care teams at their institutions to help optimize patient care. The presenters will review core palliative care medication management skills and advanced therapeutics used for complex symptom management. Add these tools to your toolbox through a fast-paced discussion of these minitopics: opioid conversions; complex pain management and the role of methadone, ketamine, lidocaine, and dexmedetomidine; screening for risk of opioid misuse and management of patients with opioid use disorder; palliative sedation; palliative extubation and withdrawal of respiratory support; refractory GI symptoms; delirium; and communication skills for the oncology pharmacist wading into palliative care.

Learning Objectives

  1. Identify strategies for assessing patients to improve the oncology patient’s symptom management through optimizing medication therapy of the oncology patient with palliative care needs.
  2. Develop a toolbox with resources to use when faced with complex symptom management challenges in the oncology patient with palliative care needs.
  3. Use patient case examples to illustrate the oncology or palliative care pharmacist’s role in challenging patient care scenarios.

Agenda

  • Palliative Care in Oncology and the Role of the Clinical Pharmacist
  • Communication Toolbox: Responding to Oncology Patients Who Are Expressing Strong Emotions
  • Opioid Tools: Conversions, Screening for Risk of Opioid Misuse and Rotating On and Off Methadone
  • Non-Pain Symptoms: Refractory Nausea/Vomiting, Constipation/Ileus/Bowel Obstruction, Anxiety, Insomnia, Delirium
  • Advanced Pain and Symptom Management: Ketamine, Lidocaine, Dexmedetomidine or Palliative Sedation

Fee: $125

Preconference-Only Fee: $100


Poster Sessions

Attend the poster sessions being held at a number of times during the conference and see the impressive work of our members. The authors will be present, making these sessions a great opportunity for networking and initiating collaboration with colleagues.

New this year: Poster sessions will be held at various times to give you maximum viewing potential!

Thursday, April 4, 11:30 am–1 pm
Trainee Research will be presented in the Exhibit Hall.

Thursday, April 4, 5–7:30 pm
Completed Research posters and the Top 10 Trainee Research posters will be presented in the Exhibit Hall.

Friday, April 5, 11 am–1 pm
Trainee Research will be presented in the Exhibit Hall.

xs
sm
md
lg